Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery
Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue that is approved for long-term obesity management in North America. While bariatric surgery remains the gold standard for weight loss, an increasing number of patients are on liraglutide in the setting of ongoing workup for bariatric surgery. The presence of gastrointestinal symptoms prior to bariatric surgery may prompt testing for dysmotility, which affects surgical decision making. Here we report six cases where treatment with liraglutide was associated with reversible reduction in gastric and esophageal motility in screening for bariatric surgery. While liraglutide is known to delay gastric emptying, there are minimal reports of how this medication affects gastrointestinal investigations used in this context. The implications of these abnormal screening investigations on candidacy for bariatric surgery are discussed.
KeywordsLiraglutide Bariatric surgery Roux-en Y Sleeve gastrectomy Gastroparesis Esophageal dysmotility
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
Dr. Modi has received speaker fees for educational events and honoraria for the development of educational materials from NovoNordisk Canada and Shire Pharma Canada. She has also received speaker fees from Valeant Canada and serves on the advisory board. Dr. Cawsey has received speaker fees and consulting fees from NovoNordisk Canada. Dr. Sharma has received speaker fees and consulting fees from NovoNordisk Canada and Merck. He also serves on the advisory board for Valeant Canada.
- 2.Novo Nordisk Canada Inc. Saxenda® Product Monograph. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf. Published 2017 July 12. Accessed 10 December 2017.
- 12.Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–73.CrossRefPubMedGoogle Scholar